78839 20200716101425.0 doi 10.1038/s41408-019-0176-x sideral 111193 ART-2019-111193 eng Rodríguez-Otero, P. Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature 2019 Access copy available to the general public Unrestricted Disease control at 5 years would be a desirable endpoint for elderly multiple myeloma (MM) patients, but biomarkers predicting this are not defined. Therefore, to gain further insights in this endpoint, a population of 498 newly diagnosed transplant-ineligible patients enrolled in two Spanish trials (GEM2005MAS65 and GEM2010MAS65), has been analyzed. Among the 435 patients included in this post-hoc study, 18.6% remained alive and progression free after 5 years of treatment initiation. In these patients, overall survival (OS) rate at 10 years was 60.8% as compared with 11.8% for those progressing within the first 5 years. Hemoglobin (Hb) = 12 g/dl (OR 2.74, p = 0.001) and MGUS-like profile (OR 4.18, p = 0.005) were the two baseline variables associated with long-term disease-free survival. Upon including depth of response (and MRD), Hb = 12 g/dl (OR 2.27) and MGUS-like signature (OR 7.48) retained their predictive value along with MRD negativity (OR 5.18). This study shows that despite the use of novel agents, the probability of disease control at 5 years is still restricted to a small fraction (18.6%) of elderly MM patients. Since this endpoint is associated with higher rates of OS, this study provides important information about diagnostic and post-treatment biomarkers helpful in predicting the likelihood of disease control at 5 years. info:eu-repo/grantAgreement/EUR/ERC/MYELOMANEXU-2015 info:eu-repo/grantAgreement/ES/ISCIII/CB16-12-00369 info:eu-repo/grantAgreement/ES/ISCIII/CB16-12-00377 info:eu-repo/grantAgreement/ES/ISCIII/CIBERONC info:eu-repo/grantAgreement/ES/ISCIII/FIS/CD13-00340 info:eu-repo/grantAgreement/ES/ISCIII/FIS/G03-136 info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI12-01761 info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI12-02311 info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI13-01469 info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI14-01867 info:eu-repo/grantAgreement/ES/ISCIII/FIS/PS09-01897-01370 info:eu-repo/semantics/openAccess by http://creativecommons.org/licenses/by/3.0/es/ 8.023 2019 2.924 2019 ONCOLOGY 25 / 244 = 0.102 2019 Q1 T1 Oncology 2019 Q1 HEMATOLOGY 6 / 76 = 0.079 2019 Q1 T1 Hematology 2019 Q1 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Mateos, M.V. Martínez-López, J. Hernández, M.T. Ocio, E.M. Rosiñol, L. Martínez, R. Teruel, A.I. Gutiérrez, N.C. Bargay, J. Bengoechea, E. González, Y. de Oteyza, J.P. Gironella, M. Nuñez-Córdoba, J.M. Encinas, C. Martín, J. Cabrera, C. (orcid)0000-0001-8515-3599 Palomera, L. Universidad de Zaragoza de Arriba, F. Cedena, M.T. Puig, N. Oriol, A. Paiva, B. Bladé, J. Lahuerta, J.J. San Miguel, J.F. 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 9, 4 (2019), 36 BLOOD CANCER JOURNAL BLOOD CANCER JOURNAL 2044-5385 151944 http://zaguan.unizar.es/record/78839/files/texto_completo.pdf Versión publicada 99783 http://zaguan.unizar.es/record/78839/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:78839 articulos driver 2020-07-16-08:44:11 ARTICLE